Clinical research challenges posed by difficult-to-treat depression

AJ Rush, HA Sackeim, CR Conway… - Psychological …, 2022 - cambridge.org
Approximately one-third of individuals in a major depressive episode will not achieve
sustained remission despite multiple, well-delivered treatments. These patients experience …

Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial

CL Raison, G Sanacora, J Woolley, K Heinzerling… - Jama, 2023 - jamanetwork.com
Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD).
Objective To evaluate the magnitude, timing, and durability of antidepressant effects and …

[HTML][HTML] Efficacy and safety of transcranial magnetic stimulation for treating major depressive disorder: An umbrella review and re-analysis of published meta-analyses …

S Brini, NI Brudasca, A Hodkinson, K Kaluzinska… - Clinical psychology …, 2023 - Elsevier
Objectives We re-analysed data from published meta-analyses testing the effects of
Transcranial Magnetic Stimulation (TMS) on Major Depressive Disorder (MDD) in adults. We …

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

RS McIntyre, M Alsuwaidan, BT Baune, M Berk… - World …, 2023 - Wiley Online Library
Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Connectivity-guided intermittent theta burst versus repetitive transcranial magnetic stimulation for treatment-resistant depression: a randomized controlled trial

R Morriss, PM Briley, L Webster, M Abdelghani… - Nature Medicine, 2024 - nature.com
Disruption in reciprocal connectivity between the right anterior insula and the left
dorsolateral prefrontal cortex is associated with depression and may be a target for …

Real world transcranial magnetic stimulation for major depression: A multisite, naturalistic, retrospective study

N Bouaziz, C Laidi, S Bulteau, C Berjamin… - Journal of Affective …, 2023 - Elsevier
Abstract Background In 2008, the US FDA approved rTMS as a treatment against medication-
resistant depression. However, real-world rTMS outcomes remain understudied. This study …

Clinically significant changes in the 17-and 6-Item Hamilton Rating Scales for Depression: a STAR* D report

AJ Rush, C South, S Jain, R Agha… - Neuropsychiatric …, 2021 - Taylor & Francis
Objective To develop clinically meaningful improvement thresholds in both the 17-item and
the 6-item Hamilton Rating Scale for Depression (HRSD) total scores in depressed …

Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial

AL Back, TK Freeman-Young, L Morgan… - JAMA Network …, 2024 - jamanetwork.com
Importance The psychological morbidity experienced by physicians, advanced practice
practitioners (APPs), and nurses from working during the COVID-19 pandemic includes …

[HTML][HTML] IN Esketamine and IV ketamine: results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment …

G Gutierrez, J Swainson, N Ravindran, RW Lam… - Psychiatry …, 2024 - Elsevier
Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage
treatment resistant depression within major depressive disorder (MDD-TRD). This is a multi …

A pilot randomized controlled trial of online written exposure therapy delivered by peer coaches to veterans with posttraumatic stress disorder

CP McLean, N Malek, CL Straud - Journal of Traumatic Stress, 2024 - Wiley Online Library
This pilot randomized clinical trial (RCT) sought to examine the preliminary efficacy of an
internet‐based version of written exposure therapy delivered to veterans through an online …